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Abstract
Background: Dementia drug development aims to modulate pathological processes that cause clinical syndromes.
Population data (epidemiological neuropathology) will help to model and predict the potential impact of such therapies on
dementia burden in older people. Presently this can only be explored through post mortem findings. We report the
attributable risks (ARs) for dementia at death for common age-related degenerative and vascular pathologies, and other
factors, in the MRC Cognitive Function and Ageing Study (MRC CFAS).
Methods and Findings: A multicentre, prospective, longitudinal study of older people in the UK was linked to a brain
donation programme. Neuropathology of 456 consecutive brain donations assessed degenerative and vascular pathologies.
Logistic regression modelling, with bootstrapping and sensitivity analyses, was used to estimate AR at death for dementia
for specific pathologies and other factors. The main contributors to AR at death for dementia in MRC CFAS were age (18%),
small brain (12%), neocortical neuritic plaques (8%) and neurofibrillary tangles (11%), small vessel disease (12%), multiple
vascular pathologies (9%), and hippocampal atrophy (10%). Other significant factors include cerebral amyloid angiopathy
(7%) and Lewy bodies (3%).
Conclusions: Such AR estimates cannot be derived from the living population; rather they estimate the relative contribution
of specific pathologies to dementia at death. We found that multiple pathologies determine the overall burden of dementia.
The impact of therapy targeted to a specific pathology may be profound when the dementia is relatively ‘‘pure,’’ but may be
less impressive for the majority with mixed disease, and in terms of the population. These data justify a range of strategies,
and combination therapies, to combat the degenerative and vascular determinants of cognitive decline and dementia.
Please see later in the article for the Editors’ Summary.
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Assessment of brain pathology in the consensus protocols for
pathological diagnosis of dementia has been based on semiquan-
titative methods [1–3]. These protocols aspire to distinguish
demented and nondemented individuals using thresholds of
plaques, neurofibrillary tangles (NFTs), infarcts, and Lewy
bodies, so that pathology becomes the ‘‘gold standard’’ for
diagnosis. This approach has progressed understanding of
clinical phenotypes, genetics, biochemistry, and molecular
pathogenesis associated with cognitive decline in older people.
Trials of disease modifying therapies are already in progress and
proponents of a vascular basis for cognitive dysfunction propose
secondary prevention strategies in older people [4]. The scale of
the clinical and social problem presented by dementia in ageing
populations presents an urgent need to assess the likely impact
and cost effectiveness of new, potentially expensive, therapies,
and to develop robust biomarkers for diagnosis and progression.
Understanding the population impact of therapies that modify
the pathobiology of dementia requires an understanding of the
burden of cognitive dysfunction directly attributable to a
particular pathology. Recently reported trials in Alzheimer
disease (AD), alleging divergent outcomes for inhibition of
amyloid gamma-secretase and tau aggregation, exemplify this
need [5,6]. These are issues about which conventional case-
control cohorts and studies in secondary referral populations,
memory clinics, or community volunteers are less informative
than the population approach used here. Selection biases are
associated with non–population-based studies of older people
and lead to unknown effects so that their conclusions may not
generalise to the whole population.
Dementia is associated with a high prevalence of mixed
Alzheimer, vascular, and other pathologies, and the thresholds
of severity that clearly distinguish between an AD brain and the
brain of a nondemented individual only capture around 20% of
demented people [7–9]. True population-based studies of
dementia combining longitudinal assessment of clinical state with
post mortem brain donation are rare but offer the only means at
present of investigating the population-level impact of pathology
on cognition [10]. The Cognitive Function and Ageing Study
(CFAS) autopsy donor cohort is now of sufficient size to facilitate
true ‘‘epidemiological neuropathology.’’ Here we present estimates
of the attributable risk of dementia at death associated with specific
neuropathological features in this cohort.
Figure 1. MRC CFAS design. Numbers of interviews and donations from interview waves.
doi:10.1371/journal.pmed.1000180.g001
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Ethics Statement
All procedures received approval from a multicentre Research
Ethics Committee. MRC Cognitive Function and Ageing Study
(MRC CFAS) is a population-based longitudinal study of people, in
their 65th year and over, enrolled from the population-based
registers ofprimary care physiciansinsixsitesinEnglandandWales
[11]. In 1990 these registers provided full geographical population
coverage including people living in institutional settings.
In each of five centres random samples generated a recruited
cohort of 2,500 individuals per centre (82% response rate) with
equal numbers below and above 75 y. Trained interviewers
conducted interviews with participants, including basic sociode-
mographic questions, cognitive examination, and items from the
Geriatric Mental State (GMS) organicity scale, activities of daily
living, physical health, and medication (see www.cfas.ac.uk).
A 20% stratified sample underwent detailed assessment (GMS
[12], augmented CAMCOG [13]) repeated after 2 y. This
assessment group included those individuals with cognitive
impairment and a random sample from the same centre. There
were two re-interview cycles of all survivors and several follow-ups
in the assessment group only. Study flow is shown in Figure 1.
Diagnoses were made usingthe validated AGECAT algorithm[14].
In the sixth centre (Liverpool) 5,200 people aged 65 y and over, in
equal numbers across 5-y bands, were recruited with a population
sampling base. This study (ALPHA) started before the other sites but its
design and methods enable it to be integrated into CFAS. Interviews in
ALPHA were based on GMS and study flow is shown in Figure 2.
Individuals, families, and carers in the assessment group were
approached by trained liaison officers and invited to participate in
counselling around brain donation. Those who agreed to brain
donation were provided with information to allow staff or family
involved in the final illness to notify the death and initiate brain
donation. Donations still proceeded, wherever possible, for cases
coming to autopsy under the coroner.
There were 456 individuals in this analysis, representing all
completed brain donations before 1st August 2004. The sample
includes 207 individuals previously described (two families
contributing to that previous cohort subsequently revoked consent
and the data were removed) [7].
Dementia status was established using multiple information
sources including AGECAT, notification of dementia in death
certificates, a retrospective informant interview (RINI; www.cfas.
ac.uk) with relatives and carers after death, and the probability of
being demented before death from a Bayesian analysis of all
individuals modelling the prevalence and incidence of dementia in
CFAS. We could not assign dementia status in 30 individuals in
whom the study diagnosis was ‘‘not dementia.’’ These respondents
were not included in the analysis because their last interview was
more than 6 mo before death, no RINI was available, and
dementia was not mentioned on the death certificate.
The neuropathology protocol used standardised assessment of
paraffin-embedded tissues to record data using the Consortium to
Establish a Registry of Alzheimer’s Disease (CERAD) protocol [2].
CERAD data were augmented by a strategy for evaluating white
matter lesions (WML) in the post mortem brain previously validated
against histopathology [15]. Neuropathology was assessed without
knowledge of clinical, interview, or RINI data. Acceptable inter-rater
reliability (,5% with scores more than 1 grade difference) was
achieved for cerebral cortical atrophy, NFT, amyloid plaques (diffuse
and neuritic), Lewy bodies, and cerebral amyloid angiopathy by
circulation of macroscopic brain photographs and microscopic slides.
Statistical Methods
Sample characteristics were compared with the overall population
using Chi-squared for association and Mann-Whitney for the median
age of death. Unconditional logistic regression analysis examined the
Figure 2. MRC Alpha Study (Liverpool) design. Numbers of interviews and donations from each interview wave.
doi:10.1371/journal.pmed.1000180.g002
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Backwards stepwise logistic regression (p=0.1) assisted model
selection. Interactions between pathologies were tested using
likelihood ratio tests. The chosen final model best predicted dementia
status at death for the least number of factors within the model. The
method maximised the sensitivity and specificity using the predicted
probabilities from the model, and minimised the number of
individuals for whom prediction was not possible.
Using the model most likely to correctly predict dementia we
estimated the partial ‘‘population attributable risk’’ (AR) at death,
conditional on all other factors, from the adjusted logistic regression
[16]. These AR estimates represent the amount of dementia at
death in the sample determined by each factor inthe model,relative
to the reference category, using both the risk and the prevalence of
that factor. The AR represents the proportion of dementia at death
accounted for after elimination of that risk factor if the remaining
distribution of the risk factors remains unchanged. Bootstrap
confidence intervals were calculated [17]. The amount of missing
data was small (,5%) except for brain weight (10%), macroscopic
vascular disease (7%) and diffuse plaques in the entorhinal campus/
hippocampus (6%). A sensitivity analysis of the model and PAR
estimates was undertaken using multiple imputations using chain
equations to impute the data for all individuals with unknown
factors in the model process [18]. Ten imputation datasets were
used. Analysis was undertaken using Stata software, version 9.2
(Stata Corp.) and the R software package (www.r-project.org).
Results
Representativeness of the Brain Donor Cohort
There were no significant differences between the donor cohort
and all respondents who died with respect to sex and length in
fulltime education (Table 1). Individuals who donated brain tissue
were significantly older than all deaths in the population sample,
and also than all individuals still alive on 1st August 2004. More
donors were in the ‘‘manual’’ social class compared with all who
Table 1. Demographic characteristics of baseline population, deaths, and donors (six centres).
Characteristics
Baseline
n=18,248 Percent IQR
Died but Not
Donors
n=11,465 Percent IQR
Donors
n=456 Percent IQR
Donors Versus
All Died but
Not Donors
Centre
Cambridge 2,601 14 — 1,465 13 — 96 21 — —
Gwynedd 2,625 14 — 1,387 12 — 9 2 — —
Liverpool 5,244 29 — 4,065 35 — 101 22 — —
Newcastle 2,524 14 — 1,549 14 — 55 12 — —
Nottingham 2,514 14 — 1,423 13 — 127 28 — —
Oxford 2,740 15 — 1,526 13 — 68 15 — —
Sex
Men 7,625 42 — 5,164 45 — 188 41 — —
Women 10,623 58 — 6,301 55 — 268 59 — p=0.11
Age group at baseline (y)
,74 8,231 45 — 3,557 31 — 100 22 — —
75–84 6,982 38 — 5,159 45 — 215 47 — —
85–94 2,849 16 — 2,573 22 — 135 29 — —
.9 4 1 8 6 1 — 1 7 6 2— 62— P,0.001
Median age (y) 70 — 67–74 79 — 73,84 81 — 76–86 —
Education
Missing 566 3 — 483 4 — 32 6 — —
0–9 y 11,985 66 — 7,812 68 — 302 67 — —
.9 y 5,697 32 — 3,170 28 — 122 27 — p=0.97
Social class
Missing 1,371 8 — 1,035 9 — 57 13 — —
Nonmanual 6,574 36 — 3,717 32 — 165 36 — —
Manual 10,303 56 — 6,713 59 — 234 51 — p=0.02
Age group at death (y)
,74 — — — 1,187 10 — 43 27 — —
75–84 — — — 4,601 40 — 125 50 — —
85–94 — — — 4,782 42 — 229 13 — —
.94 — — — 895 8 — 59 — 82–92 P,0.001
Median age at death — — — 84 — 79,90 87 — — —
IQR, interquartile range.
doi:10.1371/journal.pmed.1000180.t001
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brain donor cohort and the CFAS baseline sample with respect to
sex, social class, and length in fulltime of education.
Prevalence of Neuropathologies in Old People
Neurodegenerative pathology in the cohort is shown in Tables 2
and 3. NFT were the most prevalent degenerative pathology in the
hippocampus and entorhinal cortex (92%). In the neocortex NFT
were less (52%), and neuritic plaques more (68%), prevalent.
Neuronal loss in hippocampus and subcortical nuclei was reported
in 40% and 60% of the sample, respectively. Lewy bodies were
found in less than 10% of brains (mainly substantia nigra)
reflecting the use of older techniques (hematoxylin–eosin or
ubiquitin staining) rather than synuclein staining. These factors are
shown in relation to dementia status in Tables 4 and 5.
Neocortical, hippocampal, and entorhinal cortex pathology was
more common in individuals with dementia. Vascular pathology
was frequently observed (not demented 71%, demented 84%),
most frequently as small vessel disease (SVD; not demented 60%,
demented 77%; odds ratio [OR] for dementia 1.6, 95%
confidence interval [CI] 0.9–2.8). This diagnosis of SVD is based
exclusively on histological criteria. Periventricular white matter
lesions (PVL) were common (not demented 87%, demented 95%,
OR for dementia with severe PVL 4.3, 95% CI 1.9–9.8), though
deep white matter lesions (DWMLs) were less common (not
demented 60%, demented 73%, OR for dementia with severe
DWML 3.3, 95% 1.6–6.8). A combined diagnosis including both
WML and histological SVD was overrepresented among the
demented group (32% versus 24%; OR for dementia 2.9, 95% CI
1.6–5.5). Cerebral amyloid angiopathy (CAA) was overrepresented
in the demented group (34% versus 10%; OR for dementia 4.3,
95% CI 2.4–7.6). Neocortical and hippocampal atrophy were both
common in individuals with dementia (75% and 67%), though less
so in the nondemented (43% and 31%), and therefore have a very
large association with dementia (severe atrophy OR.10).
The multivariable logistic regression (Table 5) showed indepen-
dent associationwith dementiastatusfor:moderate and severeNFT
in the neocortex; severe neuritic plaques in the neocortex; cerebral
angiopathy; combined vascular disease; SVD; PVL; Lewy bodies;
hippocampal atrophy; brain weight and age. All respondents with
severe NFT in the neocortex (39 individuals, 16% of the demented
group) were demented givingan infinite odds ratio for dementia risk
and representing a perfect predictor (sufficient but not necessary).
Seventy individuals had some missing neuropathology measures
and were initially excluded from the modelling. Individuals whose
missing data did not affect their predicted dementia status were
included in the summary (48 of 70). The final prediction was
therefore from a model using 404 brains (89%), which represent 4%
of all the deceased respondents in CFAS.
The multivariable model (Table 5) correctly predicted dementia
status in 80% (404 individuals) of the 426 with known dementia
status (sensitivity, 71%, 95% CI 64–76; specificity, 92%, 95% CI
87–96; receiver operating characteristic [ROC] 0.86). Substantial
neuropathology without a dementia diagnosis was found in 13
Table 2. Number of individuals with neuropathology findings in medial temporal and neocortical regions.
Neuropathology Severity Hippocampus Percent Entorhinal Percent Frontal Temporal Parietal Occipital Overall Percent
Neuritic plaques None 191 42 178 39 185 171 194 200 143 31
Mild 97 21 122 27 140 111 114 74 104 23
Moderate 123 27 106 23 91 123 108 80 139 31
Severe 39 9 41 9 37 50 38 23 70 15
Missing 6 19 231 27 900
Diffuse plaques None 203 45 142 31 134 130 151 143 115 25
Mild 128 28 110 24 106 95 107 94 95 21
Moderate 84 18 124 27 94 122 92 100 112 25
Severe 16 4 51 11 103 92 88 37 120 26
Missing 25 5 29 6 19 17 18 82 14 3
Tangles None 51 11 39 9 298 230 295 299 216 47
Mild 118 26 94 21 101 124 94 38 129 28
Moderate 134 30 185 41 40 62 47 26 70 15
Severe 147 32 128 28 11 37 11 9 39 9
Missing 6 11 0 267 98 421
Neuronal loss None 287 63 287 63 432 430 430 384 425 93
Mild 67 15 53 12 10 12 7 3 19 4
Moderate 3 9 9 4 61 0 0 00 00 0
Severe 3 7 83 4 700 00 00
Missing 26 6 36 8 14 14 19 69 12 3
Lewy bodies None 432 95 409 90 433 424 428 380 425 93
Mild 6 1 13 3 8 16 4 2 18 4
Moderate 0 04 100 00 00
Severe 0 01 000 00 00
Missing 18 4 29 6 15 16 24 74 13 3
doi:10.1371/journal.pmed.1000180.t002
Epidemiological Pathology of Dementia
PLoS Medicine | www.plosmedicine.org 5 November 2009 | Volume 6 | Issue 11 | e1000180individuals (M:F 6:7; age at death, 81–102 y). This group includes
two individuals with life-long low cognition confirmed by RINI
interview. The remaining 11 had an Mini-Mental Status Exami-
nation (MMSE) .18 (three with MMSE .26) when they were last
measured, including five (45%) who had a RINI. Median time from
interview to death in those without a RINI interview was 12 mo.
Only two had symptomatic cognitive impairment, but not
consistently, and one had depression. The pathologies exhibited
by these individuals were SVD (n=11), low brain weight (n=8),
atrophy (n=7), severe plaques (n=5), and moderate NFT (n=4).
Conversely 68 individuals (M:F 24:44; age at death, 71–103 y)
had a dementia diagnosis before death but showed only modest
neuropathology. Sixty (88%) showed moderate or severe cognitive
impairment before death. Of the other eight all had died at least
15 mo after the last interview and dementia was confirmed by
RINI (n=6) or death certificate (n=3). The neuropathology was
generally mild and included Lewy bodies (n=4). Two individuals
had severe atrophy of the hippocampus. Neuropathology in the
brainstem, not included in the model, was present in 36 individuals
(NFT, n=24; plaques, n=4; neuronal loss, n=15). These factors
did not improve the overall model when tested across all
individuals. Other neuropathological findings in these individuals
include Progressive Supranuclear Palsy, hippocampal hypoxic
injury, head injury, and mesial temporal sclerosis. The outcome of
interest in this analysis was dementia and it therefore does not
address cognitive impairment short of dementia in which the
factors reported here would also be expected to play a role.
AR of Dementia for Pathological Features
The risk of dementia associated with specific thresholds of
pathology is shown in Table 5. Each estimated AR at death adjusts
for all others such that 96% of the overall risk is explained. Nearly
20% of this risk is due to the effect of age. Factors conveying more
than 8% each of the dementia risk were: NFT in the neocortex; age;
neuritic plaques; SVD; moderate/severe atrophy; low brain weight.
Alzheimer pathologies together (plaques, tangles, and CAA) account
for ,25% of dementia risk, and vascular pathologies ,21%. Other
neuropathological factors each convey between 2%–5% of the risk.
Neuropathology in the Nondemented
Many nondemented individuals manifest ‘‘high risk’’ pathologies.
A moderate NFT score in the neocortex is rare (4%), and a severe
NFT score absent, but multiple vascular disease (24%) and SVD
(47%) arecommon. Neuropathological factors, age, and brain weight
only account for 34% of the variability within the model, despite high
estimates of AR. This apparent anomaly underscores their relatively
poor predictive value in making a diagnosis of dementia.
Prediction from Neuropathology Alone
Univariate modelling of the relationship between dementia and
neuropathological findings, excluding age and brain weight, showed a
large additional risk associated with having NFT in the hippocampus.
However this adjusted out in multivariable analysis. The model based
on neuropathology data alone has higher sensitivity (83%), but lower
specificity (76%). From the 399 in this model, 80% were correctly
classified as either demented or not. The AR at death for
neuropathological features was modified only slightly by excluding
age and brain weight. The major contributor to dementia risk
remained NFT (28%; neocortical, 14%; hippocampal, 14%). Atrophy
(20%) and CAA (11%) were more important. Vascular factors (17%),
neocortical plaques (7%), and Lewy bodies (4%) remained the same.
No interactions were detected.
Table 3. Number of individuals with neuropathology findings in subcortical nuclei.
Neuropathology Severity Substantia Nigra
Nucleus
Basalis Raphe ´ Locus Ceruleus Dorsal Vagus Overall Percent
Plaques None 389 202 271 283 194 353 77
Mild 23 0 8 1 0 3 6 8
Moderate 01 3 0 0 0 1 3 3
Severe 00 0 0 0 0 0
Missing/not
measured
65 211 177 172 262 54 12
Tangles None 314 93 157 166 207 177 39
Mild 89 104 78 105 11 122 26
Moderate 13 49 52 42 0 77 17
Severe 20 47 36 14 0 71 15
Missing 20 163 133 129 238 9 2
Neuronal loss None 217 205 298 216 230 183 40
Mild 175 61 23 84 27 175 38
Moderate 36 23 2 27 14 67 15
Severe 16 6 11 3 25 6
Missing 12 161 133 118 182 6 2
Lewy bodies None 409 286 327 313 258 406 89
Mild 19 10 2 15 7 20 4
Moderate 11 1 0 9 10 18 4
Severe 80 0 1 0 9 2
Missing 9 159 127 118 181 3 1
doi:10.1371/journal.pmed.1000180.t003
Epidemiological Pathology of Dementia
PLoS Medicine | www.plosmedicine.org 6 November 2009 | Volume 6 | Issue 11 | e1000180Table 4. Number of individuals by neuropathology and dementia status at death.
Neuropathological Findings Severity No Dementia n=183 Percent Dementia n=243 Percent Uncertain n=30 Percent
Neocortex: neuritic plaques None 83 45 47 19 13 43
Mild 51 28 44 18 9 30
Moderate 43 24 89 37 7 23
Severe 6 3 63 26 1 3
Neocortex: diffuse plaques None 54 30 38 16 9 30
Mild 43 24 42 18 4 13
Moderate 56 31 60 26 9 30
Severe 28 15 91 39 8 27
Missing 12 — 12 — 0 —
Neocortex: NFT None 114 63 81 33 21 67
Mild 59 33 63 26 7 22
Moderate 8 4 60 25 2 11
Severe 0 0 39 16 0 0
Neocortex: atrophy None 101 57 57 25 15 50
Mild 51 29 52 23 12 40
Moderate 24 14 94 41 2 7
Severe 1 1 28 12 0 0
Missing 6— 1 2 — 1 —
Hippocampus: neuritic plaques None 106 58 67 28 18 60
Mild 37 20 57 24 3 10
Moderate 33 18 83 35 7 23
Severe 6 3 31 13 2 7
Missing 1— 5 — 0 —
Hippocampus: diffuse plaques None 101 56 89 40 13 43
Mild 47 26 70 32 11 37
Moderate 26 15 53 24 5 17
Severe 53 1 0 5 1 3
Missing 4— 2 1 9 0 —
Hippocampus: NFT None 34 19 12 5 5 17
Mild 68 37 39 16 11 37
Moderate 53 29 72 30 9 30
Severe 27 15 115 48 5 3
Missing 1— 5 — 0 0
Hippocampus: atrophy None 117 69 71 33 16 57
Mild 33 19 47 22 9 32
Moderate 17 11 78 36 2 7
Severe 21 1 8 8 1 4
Missing 14 — 29 — 2 2
Entorhinal cortex: neuritic plaques None 100 55 61 26 17 57
Mild 49 27 64 27 9 30
Moderate 28 15 75 32 3 10
Severe 5 3 35 15 1 3
Missing 1— 8 — 0 —
Entorhinal cortex: diffuse plaques None 81 46 51 23 10 33
Mild 42 24 58 26 10 33
Moderate 44 25 73 33 7 23
Severe 11 6 37 17 3 10
Missing 5— 2 4 — 0 —
Entorhinal cortex: NFT None 27 15 7 3 5 17
Mild 55 30 30 13 9 30
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Imputation of variables with missing data was used to test the
robustness of the model against both missing outcome variables
(30 individuals whose dementia status was not coded) and
pathology variables. The multivariable modelling after imputation
showed few differences from the original model in Table 5. The
neuropathology factors chosen to be represented in the model
were checked using ten imputation datasets. Factors associated
with dementia were remarkably stable within each imputation
dataset. The only factors that appeared to differ were whether
Lewy bodies (excluded from five datasets), severe plaques
(excluded from four datasets), age (excluded from two datasets),
Neuropathological Findings Severity No Dementia n=183 Percent Dementia n=243 Percent Uncertain n=30 Percent
Moderate 77 43 98 42 10 33
Severe 22 12 100 43 6 20
Missing 2— 8 — 0 —
Lewy bodies — 10 5 35 14 3 10
Brain weight kg – median — 1.24 — 1.11 — 1.15 —
Age at death (y) ,80 57 32 25 10 7 23
80–89 79 43 110 45 15 50
$90 47 26 108 44 8 27
CAA None 131 73 102 43 23 77
Mild 31 17 54 23 4 13
Moderate 17 10 64 27 2 7
Severe 00 1 7 7 1 3
Missing 5— 5 — 0 —
Moderate/severe CAA — 17 10 81 34 3 13
Vascular disease
Any vascular disease — 122 71 196 84 24 83
Haemorrhage — 95 9 4 1 4
Infarct — 43 24 80 34 14 48
Lacune — 30 17 62 26 7 24
SVD — 104 60 178 77 18 64
Overall vascular pathology — 18 — — — — —
None — 50 29 38 17 5 18
One of infarct/lacune/
haemorrhage
— 14 8 9 4 3 11
SVD only — 56 33 76 34 8 29
Multiple — 50 29 102 45 12 43
Missing — 18 — 13 — 2 —
Periventricular WML None 21 13 11 5 2 7
Mild 95 58 100 44 19 66
Moderate/
severe
49 29 114 51 8 28
Missing 19 — 17 — 1 —
Deep subcortical WML None 71 40 62 27 12 41
Mild 67 38 97 41 12 41
Moderate 24 14 36 15 4 14
Severe 14 8 39 17 1 3
Missing 9— 4 — 1 —
Histological/imaging vascular
disease
None — 44 25 26 11 5 17
Infarct or haemorrhage — 74 5 2 1 3
Lacunes/SVD/DWML — 84 47 130 55 11 37
Both — 43 24 77 32 13 43
Missing — 5— 5 — 0 —
doi:10.1371/journal.pmed.1000180.t004
Table 4. Cont.
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dementia.
Neuropathological Findings Age Adjusted Analysis Multivariable Analysis AR
OR 95% CI p-Value OR 95% CI Percent 95% CI
Age at death (y)
,80 1.0 — —1 . 0 ———
80–89 3.2 1.8–5.5 — 2.5 1.1–5.8 8 0–16
$90 5.2 2.9–9.4 ,0.001 3.4 1.4–8.3 10 3–16
Time since last interview (y) — — — Not included — Not included —
,1 1.0 — —— ———
.1 1.2 0.8–1.7 0.5 — — — —
Brain weight for sex (g)
Low 5.7 3.2–10 ,0.001 4.1 1.9–9.2 12 5–19
Average 2.0 1.2–34 — 2.1 1.0–4.2 5 0–11
High 1.0 — —1 . 0 ———
Neuritic plaques in neocortex
None 1.0 — —1 . 0 ———
Mild 1.2 0.7–2.2 — 1.0 — — —
Moderate 2.9 1.7–5.0 — 1.0 — — —
Severe 18.5 7.3–47 ,0.001 9.7 2.1–43 8 3–14
Diffuse plaques in neocortex — — — Not included — Not included —
None 1.0 — —— — —
Mild 1.4 0.7–2.5 — — — — —
Moderate 1.6 0.9–2.9 — — — — —
Severe 4.2 2.3–7.9 ,0.001 — — — —
NFT in neocortex
None 1.0 — —1 . 0 ———
Mild 1.3 0.8–2.1 — 1.0 0.5–1.8 — —
Moderate 8.9 4.0–20 — 7.1 2.3–22 11 5–19
Severe ‘ — ,0.001 — — — —
Neuritic plaques in hippocampus — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.9 1.1–3.3 — — — — —
Moderate 3.5 2.1–5.9 — — — — —
Severe 8.5 3.2–22 ,0.001 — — — —
Diffuse plaques in hippocampus — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.5 0.9–2.5 — — — — —
Moderate 2.0 1.1–3.5 — — — — —
Severe 2.2 0.7–7.2 0.06 — — — —
Tangles in hippocampus — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.3 0.6–2.8 — — — — —
Moderate 2.7 1.2–5.9 — — — — —
Severe 8.4 3.7–19 ,0.001 — — — —
Neuritic plaquesin the entorhinal cortex — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.9 1.1–3.1 — — — — —
Moderate 3.7 2.1–6.5 — — — — —
Severe 11.1 4.0–30 ,0.001 — — — —
Diffuse plaquesin the entorhinal cortex — — — Not included — Not included —
None 1.0 — —— ———
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OR 95% CI p-Value OR 95% CI Percent 95% CI
Mild 2.2 1.3–3.8 — — — — —
Moderate 2.6 1.5–4.4 — — — — —
Severe 5.5 2.5–12 ,0.001 — — — —
Tangles in entorhinal cortex — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.7 0.6–4.5 — — — — —
Moderate 3.4 1.4–8.6 — — — — —
Severe 12.7 4.8–34 ,0.001 — — — —
CAA
None 1.0 — — 1.0 1.0 — —
Mild 1.9 1.1–3.3 — 1.8 0.8–3.8 2 0–6
Moderate 4.0 2.2–7.4 — 2.9 1.2–6.8 5 1–10
Severe ‘ — ,0.001 2.9 1.2–6.8 5 1–10
Moderate/severe CAA — — — Not included — Not included —
No 1.0 — —— ———
Yes 4.3 2.4–7.6 ,0.001 — — — —
Lewy bodies
No 1.0 1.0 — 1.0 — — —
Yes 3.2 1.5–6.9 ,0.003 3.5 1.3–9.3 3 1–7
Vascular disease (VD) — — — Not included — Not included —
None 1.0 — —— ———
One of infarct/lacune/haemorrhage 0.7 0.3–1.9 — — — — —
SVD only 1.6 0.9–2.8 — — — — —
Multiple 2.5 1.4–4.3 ,0.004 — — — —
Overall vascular pathology
None 1.0 — —1 . 0 ———
Infarcts/haemorrhage 1.0 0.3–3.8 — 2.4 0.4–12 — —
SVD/WML/lacunes 2.5 1.4–4.4 — 3.7 1.5–9.6 12 3–19
Both 2.9 1.6–5.5 ,0.003 4.8 1.9–12 9 3–15
Periventricular WML — — — Not included — Not included —
None 1.0 — —— ———
Mild 2.0 0.9–4.5 — — — — —
Moderate/severe 4.3 1.9–9.8 ,0.001 — — — —
Deep subcortical WML — — — Not included — Not included —
None 1.0 — —— ———
Mild 1.6 1.0–2.6 — — — — —
Moderate 1.6 0.9–3.1 — — — — —
Severe 3.3 1.6–6.8 ,0.01 — — — —
Hippocampal atrophy
None 1.0 1.0 — 1.0 1.0 — —
Mild 2.2 1.3–3.9 — 1.8 0.9–3.7 2 0–6
Moderate 6.9 3.7–13 — 3.4 1.5–7.5 8 2–15
Severe 11.1 2.5–50 ,0.001 3.4 1.5–7.5 8 2–15
Neocortical atrophy — — — Not included — Not included —
None 1.0 1.0 — — — — —
Mild 1.6 1.0–2.8 — — — — —
Moderate 5.9 3.3–10 — — — — —
Severe 37.8 5.0–29 ,0.01 — — — —
doi:10.1371/journal.pmed.1000180.t005
Table 5. Cont.
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included in the model. Two factors that were not previously in the
models became important: NFT in the hippocampus and neuronal
loss in the brainstem. Neuronal loss in the brainstem appeared
important in individuals previously misclassified, but did not
improve the model using the original data where there was missing
data in the covariates and outcome variable. The full model with
all these factors is shown in Table 6. The estimations of AR at
death were very similar for the imputation datasets. The inclusion
of brain stem neuronal loss (AR 13%) and NFT in the
hippocampus (AR 5%) emerged from small reductions (1%) in
the majority of factors though hippocampal atrophy (8% to 4%)
and old age (11% to 8%) were more affected. Analysis adjusting
for demographic differences between the brain donor cohort and
the rest of the population that died showed only slight change in
AR at death for factors most associated with older age (old age,
atrophy, and neocortical NFT), whilst vascular disease, low brain
weight, plaques, and CAA all showed small increases (1%–2%).
Only low brain weight (from 11% to 18%) and atrophy (from 8%
to 2%) were affected by the age difference between the donor
cohort and all those who died in the population. A further
sensitivity analysis only in those assessed less than 1 y prior to
death was undertaken and all associations increased in strength,
suggesting any bias is conservative, and all AR estimates were
consistent with the confidence intervals presented.
Discussion
MRC CFAS shows that it is possible to set up and sustain a
brain donation programme from a geographically dispersed,
population-based study, which is not biased in terms of gender,
social class, education, institutionalisation, or access to health care.
The resulting brain donor sample is of sufficient size to generate
meaningful estimates of AR at death associated with specific
pathologies and contributes significantly to understanding the
pathobiology of dementia on the basis of ‘‘epidemiological
neuropathology.’’ It also allows the separation of factors that
might be amenable to modification from others that may not. The
main contributors to AR at death for dementia in MRC CFAS
were age (18%), small brain (12%), neocortical neuritic plaques
(8%) and neurofibrillary tangles (11%), small vessel disease (12%),
multiple vascular pathologies (9%), and hippocampal atrophy
(10%). Other significant factors include cerebral amyloid angiop-
athy (7%) and Lewy bodies (3%).
Earlier CFAS analysis showed that Alzheimer pathology and
vascular disease are frequently found in both demented and
nondemented people [7]. In the present more detailed analysis,
with larger numbers, a moderate or severe neocortical NFT score
emerged as the best pathological discriminator between the
demented and nondemented groups. SVD emerged as an
independent contributor to dementia risk in keeping with the
evidence that SVD is the substrate for ‘‘subcortical vascular
dementia’’ and contributes a major part of the burden of vascular
cognitive impairment in the population [19]. We included deep
subcortical WMLs within the vascular disease variable on the basis
of evidence that they arise through vascular mechanisms [20]. The
estimates of AR at death reveal the relative importance of
conventional pathological measures at the population level and
show a range of pathological features contributing independently
to dementia.
The major independent effects of age and relative low brain
weight are interesting. The findings imply that other factors, not
captured in this standardised approach to pathological analysis,
are determinants of cognitive trajectory in older people. These
may include synaptic integrity and the concentrations of peptide
oligomers [21,22] but also interindividual variation in diverse
factors that determine the neurobiological basis of ‘‘brain reserve,’’
both innate (synaptic and neuronal density achieved into adult life,
potential for neurogenesis, synaptic plasticity) and acquired
(educational attainment, sustained intellectual, social, or physical
activity in mid-life and old age) [23].
Limitations of the Study
In these six population samples from England and Wales the
baseline response rate was good and unlikely to have been severely
biased. Considerable attrition over time determines that those who
remain in the study tend to have been younger and fitter at
enrolment [24]. The cohort reported here is based on individuals
who were selected for more detailed assessment at the baseline and
year 2 waves. Selection to this group is weighted towards the
cognitively impaired, but with random selection from the full
population, and created an older sample than the remainder of the
baseline sample who died within the study period. Causes of death
were similar in the two groups. Because the characteristics of both
samples are known, a sensitivity analysis backweighting for this
process (and for biases arising from selection into the neuropa-
thology cohort) adequately adjust for these sampling effects,
though not for unknown biases.
The number of interviews achieved for each individual during
the study varied (96% had at least two and 30% had five or more).
The AGECAT algorithm, applied to the data at last interview, has
been validated against clinical diagnoses and shown to be
comparable to Diagnostic and Statistical Manual of Mental
Disorders, Third Edition, Revised (DSM-IIIR) [25]. Fieldwork
interviews were rarely started in acutely ill individuals so that
diagnoses are unlikely to be influenced by confusional states.
Although dementia on death certificates, insensitive but highly
specific, was used to find incident dementia between last interview
and death it was not used to indicate that an individual was not
demented [26,27]. Clinical judgements from informant reports
were based on DSM-III-R, consistent with the previous validation
studies using the GMS instrument. The extent of misclassification
that would be necessary to create the findings observed here would
need to be extreme and, when including only those with most
recent interview data, the results are not affected.
Our previous report, clinically allocating differential diagnoses
with a predominance of mixed pathology, remains robust [7]. The
factors identified in this analysis coexist and may interact
mechanistically. Our analysis does not allow us to elucidate causal
directions, which are better investigated using longitudinal analysis
and in experimental work. A formal analysis of interactions
between vascular and degenerative pathologies will be reported
separately but the models here did not reveal interactions. The low
prevalence of Lewy bodies in this sample (,10%), reflects methods
that were not optimised for the detection and screening of a-
synucleinopathy because the neuropathology protocol predates the
recognition of dementia with Lewy bodies, and the discovery of a-
synuclein in Lewy bodies. Recent data on a subset of this cohort
show synucleinopathy in 37% but no strong association with
dementia [28]. Our data on brain weight are based on
comparisons within sex but this measure does not distinguish
atrophy from innate smallness, an issue that can only be addressed
by systematic measurement of total cranial volume. Nor does it
distinguish the contribution of vascular and neurodegenerative
processes, or other correlates such as synaptic and dendritic loss
that were not routinely measured in the pathology protocol.
Standardised and validated assessment of vascular pathology is
also needed in studies of the pathological correlates of dementia
Epidemiological Pathology of Dementia
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that they derive from individuals who have died. People with
dementia live for a variable length of time during which burdens of
neuropathology are assumed to change. To extrapolate from this
sample to an equivalent cross section of the living older population
is problematic but, in the absence of methods to achieve in vivo
measurement of all pathologies, this is the closest estimate it is
currently possible to produce. In due course these data can be
combined with modelling of in vivo population pathology derived
from techniques to assess vascular and neuropathological changes
(e.g., amyloid positron emission tomography [PET] scans).
The pathological features that are associated with dementia in
this analysis are well supported by data from other large
community-based and population-based studies. There is general
agreement from studies of older people in the UK and the US that
dementia is predominantly associated with mixed vascular and
Table 6. Sensitivity analysis: Imputation models.
Neuropathological Findings Multivariable Model Original Imputed Imputation Model
OR 95%CI OR 95% CI OR 95%CI AR 95% CI
Age at death
,80 y 1.0 — 1.0 — 1.0 —— —
80–89 y 2.5 1.1–5.8 2.3 1.1–4.8 2.1 1.0–4.5 7 1–14
$90 y 3.4 1.4–8.3 4.3 2.0–9.5 4.2 1.8–9.6 8 2–16
Brain weight for sex
Low 4.1 1.9–9.2 4.3 2.0–9.2 4.3 1.9–9.6 12 5–19
Average 2.1 1.0–4.2 1.8 0.9–3.4 1.7 0.9–3.4 4 0–9
High 1.0 — 1.0 — 1.0 —— —
Neuritic plaques in neocortex
None or mild 1.0 — 1.0 — 1.0 —— —
Moderate or severe 9.7 2.1–43 4.4 1.6–12 3.9 1.3–11 7 3–17
Tangles in neocortex
None 1.0 — 1.0 — 1.0 —— —
Mild 1.0 0.5–1.8 1.0 0.6–1.8 0.7 0.4–1.4 ——
Moderate or severe 7.1 2.3–22 6.3 2.6–15 4.6 1.8–12 10 5–17
Tangles in hippocampus
None or mild — — — — 1.0 —— —
Moderate or severe Not included — Not included — 1.8 1.0–3.3 5 0–12
CAA
None 1.0 — 1.0 — 1.0 —— —
Mild 1.8 0.8–3.8 1.7 0.9–3.3 1.5 0.7–3.0 ——
Moderate or severe 2.9 1.2–6.8 3.5 1.7–7.4 3.8 1.7–8.2 4 0–9
Lewy bodies
No 1.0 — 1.0 — 1.0 —— —
Yes 3.5 1.3–9.3 3.7 1.6–8.9 2.2 0.9–5.7 2 0–5
Overall vascular pathology
None 1.0 — 1.0 — 1.0 —— —
Infarcts/haemorrhage 2.4 0.4–12 1.9 0.3–11 1.4 0.2–9.4 ——
SVD/DWML/lacunes 3.7 1.5,9.6 3.1 1.4–6.9 3.3 1.4–7.5 ——
Both 4.8 1.9–12 4.0 1.8–9.2 4.2 1.8–9.9 20 8–33
Hippocampal atrophy
None 1.0 — 1.0 1.0 1.0 —— —
Mild 1.8 0.9,3.7 1.5 0.8–2.9 1.3 0.6–2.6 ——
Moderate 3.4 1.5–7.5 2.8 1.4–5.6 1.9 0.9–4.2 4 0–10
Severe — — — — — — — —
Brainstem neuronal loss
None — — — — 1.0 1.0 ——
Mild — — — — 2.7 1.5–4.9 6 1–12
Moderate — — — — 3.3 1.4–8.0 7 0–13
Severe Not included — Not included — 9.9 1.8–54 7 0–13
doi:10.1371/journal.pmed.1000180.t006
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degree (e.g., synucleinopathy) [30–32]. Those studies also
contribute important insights into the potential interactions of
vascular and degenerative pathologies that are not dealt with in
the present analysis [30–35]. Some studies have emphasised the
significance of microscopic infarcts compared to macroscopic
infarcts in explaining the relationship between pathology and
dementia [30,32,34], whereas others have not demonstrated an
independent association of dementia risk with microscopic
infarction [31,35]. In the present analysis we did not treat
microinfarcts as a single pathological variable. Rather we chose to
incorporate them into a global assessment of significant intrinsic
SVD that also included microscopic evidence of severe arteriolar
sclerosis and the presence of severe white matter attenuation. The
Adult Changes in Thought study (ACT) has estimated the OR for
dementia associated with Lewy bodies to be 5.1 (95% CI 1.37–
18.96) on the basis of a-synuclein immunocytochemistry com-
pared to 3.5 (95% CI 1.3–9.3) in this study using a less reliable
method of detection. The estimates of AR at death for Lewy body
pathology are 10% in ACT and 3% in MRC CFAS as reported
here. In a subgroup of this CFAS cohort we demonstrated
synucleinopathy in 37% of donated brains [28]. Other large
cohorts have reported no clear predictive relationship between
Lewy body pathology and dementia [36]. Interpretation of data on
Lewy body pathology in published multivariable analyses is further
complicated by the recent recognition of ‘‘amygdala predominant
disease’’ that may not be reliably detected using some screening
protocols. Another pathology recently emphasised in older people
is hippocampal sclerosis (HS), which has been shown to contribute
a relative risk for dementia of 2.43 (95% CI 1.01–5.85). This is a
microscopic diagnosis that was not included as a separate variable
in our data. While we did include macroscopic hippocampal
atrophy, and found that it contributes 10% of the AR at death for
dementia, it is important for future studies to determine the
correlation between macroscopic changes and the microscopic
features of HS, which are also not yet the subject of diagnostic
consensus or interlaboratory validation.
The present study supports the view that interventions that
modify neuropathology related to dysmetabolism of specific
proteins(bA4, tau)have the potential to impact on the population
burden of dementia. In the context of presymptomatic treatment
many individuals without risk of developing dementia would also
be treated unless the predictive ability of clinical tests improves
dramatically. However the estimates in this analysis indicate that
individual pathologies contributeo nl ym o d e s t l yt ot h eo v e r a llr i s k
of dementia and emphasise the need to develop a range of
protective strategies. Other factors, potentially less amenable to
intervention play a role including age, and underlying innate or
acquired factors relating to brain reserve, which, along with the
effects of multiple pathological comorbidities, all play a part in
the manifestation of dementia at the level of the population as a
whole.
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Background. Losing one’s belongings and forgetting
people’s names is often a normal part of aging. But
increasing forgetfulness can also be a sign of dementia, a
group of symptoms caused by several disorders that affect
the structure of the brain. The commonest form of dementia
is Alzheimer disease. In this, protein clumps called plaques
and neurofibrillary tangles form in the brain and cause its
degeneration. Vascular dementia, in which problems with
blood circulation deprive parts of the brain of oxygen, is also
common. People with dementia have problems with two or
more ‘‘cognitive’’ functions—thinking, language, memory,
understanding, and judgment. As the disease progresses,
they gradually lose their ability to deal with normal daily
activities until they need total care, their personality often
changes, and they may become agitated or aggressive.
Dementia is rare before the age of 65 years but about a
quarter of people over 85 years old have dementia. Because
more people live to a ripe old age these days, the number of
people with dementia is increasing. According to the latest
estimates, about 35 million people now have dementia and
by 2050, 115 million may have the disorder.
Why Was This Study Done? There is no cure for dementia
but many drugs designed to modulate specific abnormal
(pathological) changes in the brain that can cause the
symptoms of dementia are being developed. To assess the
likely impact of these potentially expensive new therapies,
experts need to know what proportion of dementia is
associated with each type of brain pathology. Although
some brain changes can be detected in living brains with
techniques such as computed tomography brain scans, most
brain changes can only be studied in brains taken from
people after death (post mortem brains). In this study, which
is part of the UK Medical Research Council Cognitive
Function and Ageing Study (MRC CFAS), the researchers
look for associations between dementia in elderly people
and pathological changes in their post mortem brains and
estimate the attributable-risk (AR) for dementia at death
associated with specific pathological features in the brain.
That is, they estimate the proportion of dementia directly
attributable to each type of pathology.
What Did the Researchers Do and Find? Nearly 20 years
ago, the MRC CFAS interviewed more than 18,000 people
aged 65 years or older recruited at six sites in England and
Wales to determine their cognitive function and their ability
to deal with daily activities. 20% of the participants, which
included people with and without cognitive impairment,
were then assessed in more detail and invited to donate
their brains for post mortem examination. As of 2004, 456
individuals had donated their brains. The dementia status of
these donors was established using data from their
assessment interviews and death certificates, and from
interviews with relatives and carers, and their brains were
carefully examined for abnormal changes. The researchers
then used statistical methods to estimate the AR for
dementia at death associated with various abnormal brain
changes. The main contributors to AR for dementia at death
included age (18% of dementia at death was attributable to
this factor), plaques (8%), and neurofibrillary tangles (11%) in
a brain region called the neocortex, small blood vessel
disease (12%), and multiple abnormal changes in blood
vessels (9%).
What Do These Findings Mean? These findings suggest
that multiple abnormal brain changes determine the overall
burden of dementia. Importantly, they also suggest that
dementia is often associated with mixed pathological
changes—many people with dementia had brain changes
consistent with both Alzheimer disease and vascular
dementia. Because people with dementia live for variable
lengths of time during which the abnormal changes in their
brain are likely to alter, it may be difficult to extrapolate
these findings to living populations of elderly people.
Furthermore, only a small percentage of the MRC CFAS
participants have donated their brains so the findings of this
study may not apply to the general population. Nevertheless,
these findings suggest that the new therapies currently
under development may do little to reduce the overall
burden of dementia because most people’s dementia
involves multiple pathologies. Consequently, it may be
necessary to develop a range of strategies and
combination therapies to deal with the ongoing dementia
epidemic.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000180.
N The US National Institute on Aging provides information
for patients and carers about forgetfulness and about
Alzheimer disease (in English and Spanish)
N The US National Institute of Neurological Disorders and
Stroke provides information about dementia (in English
and Spanish)
N The UK National Health Service Choices Web site also
provides detailed information for patients and their carers
about dementia and about Alzheimer disease
N MedlinePlus provides links to additional resources about
dementia and Alzheimer disease (in English and Spanish)
N More information about the UK Medical Research Council
Cognitive Function and Ageing Study (MRC CFAS) is
available
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